win Federal Courts Injunctions to Combat Counterfeits
PROVIDENCE, R.I.--(BUSINESS WIRE)--Dreams USA, Inc. has secured two preliminary injunctions against alleged infringers of its trademarked and copyrighted Sonny Angel ®, HIPPERS ® ® mini-figures.
The surging popularity of Dreams' products has spawned a stream of counterfeit products entering the U.S. market. Dreams continues to police and pursue legal action against infringers, including kiosk operators, C-store owners, franchisees, brick-and-mortar stores, web-based platforms, and social media sellers to prevent the sale of unauthorized and inferior products to unsuspecting consumers, and to protect our authorized distributors from financial harm. Dreams USA is the only lawful source for Sonny Angel ®, HIPPERS ® and Smiski ® products in the Americas. Authentic Sonny Angel ®, HIPPERS ® and Smiski ® products and a list of authorized U.S. distributors can be found at www.sonnyangelusa.com.
Retailers that have purchased counterfeit products are urged to remove immediately these items from their shelves and online stores and to maintain all records of purchases and sales.
For further information and to report counterfeits, please contact:
Dreams USA, Inc.
2 Charles Street Unit 3B, Providence, RI 02904
Report_Counterfeits@Dreams6USA.com
About Dreams USA
Founded in 2009, Dreams USA, Inc. is the exclusive North and South American distributor of limited-edition art toys, giftware, and lifestyle accessories created by affiliate Dreams Inc. (Japan). Its products are sold online at SonnyAngelUSA.com and at select, authorized retailers throughout the Americas.
Among Dreams' most popular items are a line of collectible mini-figures that are offered for sale and sold in connection with the trademarks Sonny Angel ®, Smiski ® and HIPPERS ®. Sonny Angel ® mini-figures have existed for over twenty years and have seen an explosion in popularity in the United States in recent years. SMISKI ® mini-figures have been extensively marketed and sold for ten years and continue to grow in popularity in the United States. HIPPERS ® are decorative mini-figures that present a new way to display Sonny Angel ®, Smiski ® and other characters. HIPPERS ® can be attached decoratively to a computer monitor, smartphone, photo frame or other flat surfaces.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development
MELBOURNE, Australia and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces the appointment of Louise Peacock as Chief Regulatory and Quality Officer, based at the Company's Oxford, UK site. With more than 35 years in the pharmaceutical industry, Louise brings extensive and highly relevant experience to Aravax having previously made key contributions to the approval of Palforzia® - the first and only FDA approved oral immunotherapy (OIT) to treat peanut allergy. Louise has held prior roles as Chief Regulatory Affairs and Quality Officer at Vaderis Therapeutics AG and Alladapt Immunotherapeutics and was Head of Pharma R&D at Nestle Health Science/Aimmune Therapeutics (acquired by Nestle Health Science in 2020) where she had broad responsibilities for global regulatory affairs across pharma products in food allergy, gastrointestinal and metabolic disorders. Whilst at Aimmune, Louise was responsible for activities supporting the development and marketing approvals for Palforzia® in the US, EU, UK and Switzerland. Louise's early career included senior positions at Abbott Laboratories, Auxilium Pharmaceuticals, Intermune and Circassia. Louise received her BSc (Hons) Pharmacology from Kings College, London and her LLB (Hons) from the University of West London. Louise Peacock, Chief Regulatory and Quality Officer of Aravax, said, 'Despite recent advances, food allergy remains an ever-growing and life-threatening problem around the world and there is a critical need for better therapies. Having followed Aravax's developments, I am convinced that PVX108 has the potential to be a life-changing alternative for patients with peanut allergy. I look forward to joining what is a world-class team and to bringing my experience to bear on the rapid further development of PVX108 and other products.' Dr Pascal Hickey, CEO of Aravax, said, 'Louise's experience in regulatory affairs in the field of food allergy is unique. It spans all the major regulatory bodies and multiple programs including the successful approval of Palforzia®. We are enormously excited that she is joining the Aravax team.' About Aravax Aravax is a clinical stage biotechnology company focused on revolutionising the treatment of food allergies with next-generation, disease-modifying immunotherapies which are safer and more convenient than existing approaches. Aravax's proprietary platform generates engineered peptides that precisely retrain the immune system and restore the body's ability to safely tolerate food allergens, without putting patients at risk of treatment-induced acute allergic reactions, including anaphylaxis. The lead product, PVX108, is currently being studied in an international Phase 2 trial for the treatment of peanut allergy. Aravax is also developing a pipeline of products tackling additional significant food allergy indications. Aravax is an international company headquartered in Melbourne, Australia with a subsidiary in Oxford, UK and operations in USA and Europe. Aravax's investors include leading international and Australian investors including Novartis Venture Fund, Brandon Capital, Tenmile, Breakthrough Victoria, Uniseed and UniSuper. For more information visit: For further information please contact Media – AustraliaKirrily Davis, E: kdavis@ M: +61 (0)401 220228 Media - InternationalSue Charles, Charles Consultants E: M: +44 (0)7968 726585Chris Gardner, E: Chris@ M: +44 (0)7956 031077Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
35 minutes ago
- Business Upturn
CEOs of The LYCRA Company and Qore® Join Global Fashion Summit Lineup
Wilmington, Del., United States: The LYCRA Company, a global leader in developing sustainable fibers and solutions for the apparel industry, announced today that its CEO, Gary Smith, is a speaker at the Global Fashion Summit: Copenhagen Edition 2025. He will be joined on stage by Jon Veldhouse, CEO of Qore®, the maker of QIRA®, a next-generation BDO and a key ingredient in bio-derived LYCRA® fiber, which is launching later this year. This press release features multimedia. View the full release here: LYCRA® brand and QIRA® are principal sponsors of the Global Fashion Summit: Copenhagen Edition 2025. The brands are exhibiting at the event, where they will promote bio-derived LYCRA® fiber made with QIRA®, derived from field corn, to help make fashion more sustainable. Smith and Veldhouse will discuss the development of this sustainable fiber made from annually renewable field corn during their Fireside Chat: From Farm to Fashion. Their session takes place on Wednesday, June 4, at 3:35 CEST in the DR Concert Hall. The discussion will be moderated by Amy Nguyen, a researcher, writer, and founder of Sustainable & Social. This is the first time both companies are participating in the Global Fashion Summit, a premier platform focused on sustainability in the fashion industry. The companies have a prominent exhibit space for attendees to learn more about bio-derived LYCRA® fiber made with QIRA®. Here, visitors can be transported to the Qore® site and cornfields in Iowa through a virtual reality experience. Bio-derived LYCRA® EcoMade fiber will be the world's first large-scale, commercially available renewable elastane. It delivers equivalent performance to the original LYCRA® fiber and serves as a one-to-one replacement with no re-engineering of fabrics, processes, or garment patterns required. The product contains 70 percent renewable content and can potentially reduce the carbon footprint of LYCRA® fiber by up to 44 percent*. The LYCRA Company holds patents related to this renewable fiber in several regions including Europe. 'We're proud to join the Global Fashion Summit for the first time and showcase how collaboration can accelerate a more sustainable future for fashion,' said Gary Smith, CEO of The LYCRA Company. 'Partnering with Qore® has enabled us to scale innovation that is renewable and ready to meet the demands of global fashion brands striving to meet their sustainability goals.' The newly constructed Qore® site in Eddyville, Iowa, began operating last month and has started producing QIRA®. The company will host a grand opening celebration in July. 'Starting production at our new state-of-the-art facility marks a major step forward—not just for Qore®, but for the entire industry,' said Jon Veldhouse, CEO of Qore®. 'With QIRA® now being made in Iowa from annually renewable field corn, we're turning sustainable innovation into reality and helping our partners bring next-generation materials to market.' Learn more about this renewable offering by visiting *Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll Americas Engineering Solutions, Inc. About The LYCRA Company The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers' products by offering unique innovations that meet the consumer's need for comfort and lasting performance. Learn more at About Qore® LLC Formed through a joint venture by Cargill and HELM AG, Qore® helps leading brands replace fossil-based chemistries with bio-derived intermediates. At the heart of the joint venture is the production of QIRA®, the next-generation bio-derived 1,4-butanediol (BDO). Made biologically through the fermentation of plant-based sugars, QIRA® can save up to 86% of greenhouse gas emissions when replacing today's widely used chemical intermediates made from traditional fossil sources. Bio-derived QIRA® can be used the same way as its fossil counterpart but with significantly better environmental performance. For more information and inquiries, visit About The Global Fashion Summit Global Fashion Summit is a leading international forum for sustainability in fashion, presented by Global Fashion Agenda (GFA). Convening major decision makers from across the world, the forum was first launched in 2009 and has become a nexus for agenda-setting discussions and presentations on the most critical environmental, social and ethical issues facing our industry and planet, all intended to spark urgent action and accelerate impact in the industry. Learn more at LYCRA® is a trademark of The LYCRA Company. QIRA® is a trademark of Qore®. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Business Insider
an hour ago
- Business Insider
Rubrik, Inc. Class A (RBRK) Receives a Buy from Barclays
In a report released on May 30, Saket Kalia from Barclays maintained a Buy rating on Rubrik, Inc. Class A (RBRK – Research Report), with a price target of $105.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Kalia covers the Technology sector, focusing on stocks such as Adobe, Autodesk, and PTC. According to TipRanks, Kalia has an average return of 16.7% and a 64.69% success rate on recommended stocks. In addition to Barclays, Rubrik, Inc. Class A also received a Buy from Guggenheim's John Difucci in a report issued on May 27. However, on May 15, Mizuho Securities downgraded Rubrik, Inc. Class A (NYSE: RBRK) to a Hold. Based on Rubrik, Inc. Class A's latest earnings release for the quarter ending January 31, the company reported a quarterly revenue of $258.1 million and a GAAP net loss of $114.89 million. In comparison, last year the company earned a revenue of $175.01 million and had a GAAP net loss of $97.5 million Based on the recent corporate insider activity of 96 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RBRK in relation to earlier this year. Most recently, in April 2025, Ravi Mhatre, a Director at RBRK sold 13,213.00 shares for a total of $832,154.74.
